The Efficacy and Safety of Anticoagulation in Chinese Patients With Non-ST Segment Elevation Acute Coronary Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1800 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-07-31

Study Completion Date

2011-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of the EASY-CHINA Registry is to describe the clinical epidemiology of Chinese patients with NSTE-ACS, to evaluate their current anticoagulation management in China, and the resources used for it.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Application of MDCT in Coronary Artery Disease

NCT00155012

Coronary Arteriosclerosis

UNKNOWN

Renal Artery Fibromuscular Dysplasia Registry

NCT05363748

Renal Artery Fibromuscular Dysplasia

RECRUITING

Taiwan Cohort - Chronic ThromboEmbolic Pulmonary Hypertension Registry

NCT03667391

The Geodemographics of CTEPH in Taiwan

UNKNOWN

Normal Reference Values in Han Adults of Extremity Arterial Structure and Hemodynamics by High-frequency Ultrasound

NCT05970926

Healthy Volunteer Artery Disease

UNKNOWN

Super Chinese Nephrotic Syndrome Registration System (SUCCESS)

NCT03001934

Nephrotic Syndrome

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Non-ST-elevated acute coronary syndromes (NSTE-ACS)are the leading cause of emergency medical care in the USA. In China, these syndromes have also become the major causes of morbidity and mortality and account for several thousands of death and hospitalizations annually. Anti-platelet drugs, anticoagulants and intervention therapy for high-risk NSTE-ACS patients may increase bleeding events while reducing ischemic coronary events. There are some evidences supporting the association between hemorrhagic complications and short- and long-term mortality. Therefore, future advances in antithrombotic therapy for NSTE-ACS need to focus on reducing ischemic event rates without increasing hemorrhagic complication rates. In this general framework, there is the need for an appropriate adoption of the available evidences concerning therapeutic strategies, specifically the use of the different antithrombotic strategies, in real world patients in order to further improve their outcomes.The primary objective of this study is to describe the clinical epidemiology of Chinese patients with NSTE-ACS, and to evaluate their current management in China. This study will be an observational survey, thus zero interference is emphasized throughout it. No randomization, blinding or special treatment will be assigned for the subjects. Issues concerning the care of subjects are completely left to the discretion of investigators in order to collect the real-world information about the pharmacological treatments for NSTE-ACS patients in china.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Coronary Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

anticoagulant

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* with symptoms of UA or MI without persistent ST elevation and at least 1 of the following additional criterias: 1)troponin T or I or CK-MB above the upper limit of normal,2)electrocardiogram (ECG) changes compatible with ischemia (ie, ST depression at least 1mm in 2 contiguous leads or T-wave inversion \>3 mm),3)any dynamic ST shift or transient ST elevation
* Must be willing to signed informed consent
* age from 21-80 years
* without pregnancy or under contraception

Exclusion Criteria

* age\<20 or \>80 years
* any contraindication to anticoagulant
* hemorrhagic stroke within 12 months
* indication for anticoagulation other than ACS
* prior enrollment in anticoagulants trials in ACS
* revascularization procedure performed for the qualifying event in one month
* severe renal insufficiency (ie,serum creatinine\>=3 mg/dL or 265umol/L)
* pregnancy or breast-feeding women
* life expectancy\<6 months
* enrollment in other medicine trials in 3 months
* with mental illness or uncooperative

Minimum Eligible Age

21 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No